6:14 PM
 | 
Sep 04, 2012
 |  BC Extra  |  Politics & Policy

G-BA head: AMNOG criticisms 'unfounded'

Josef Hecken, chairman of Germany's Federal Joint Committee (G-BA), released an interim analysis of drug benefit assessments under AMNOG and concluded that industry criticism of the pricing law is "unfounded." He noted that G-BA has found at least some degree...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >